Torrent Pharmaceuticals will participate in an investor meet on August 14, 2026, as part of the Emkay Confluence 2026 event in Mumbai. The company disclosed the schedule in a filing with the Bombay Stock Exchange and the National Stock Exchange of India Ltd on August 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The engagement is designed to provide stakeholders with direct access to company management through both group presentations and individual consultations. This interaction allows investors to discuss strategic updates and operational performance directly with executives.

Meeting Schedule

The details of the upcoming investor interaction are outlined below:

The company noted that the schedule is subject to change due to any exigencies on the part of the company or the investors.

Regulatory Disclosure

The announcement was signed by Chintan Trivedi, Company Secretary of Torrent Pharmaceuticals Limited. The filing serves as a formal intimation to the exchanges regarding the company's compliance with mandatory disclosure norms for investor interactions.

Torrent Pharmaceuticals has been assigned an Environmental, Social, and Governance (ESG) rating of 70 by NSE Sustainability Ratings and Analytics Limited. The rating agency, which is registered with the Securities and Exchange Board of India (SEBI), conducted an independent assessment of the pharmaceutical company’s sustainability practices. This disclosure provides investors with a standardized metric to evaluate the firm’s non-financial performance risks and opportunities.

The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) regarding the rating assignment on August 11, 2026. The intimation was issued pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, which mandates transparency in ESG rating disclosures for listed entities.

Rating Details

The specific details of the ESG assessment are outlined below:

Chintan M. Trivedi, Company Secretary at Torrent Pharmaceuticals, signed the regulatory filing. The notification confirms that the rating was derived through an independent evaluation process, ensuring objectivity in the assessment of the company’s environmental impact, social responsibility, and governance structures.

What the Numbers Show

An ESG score of 70 places Torrent Pharmaceuticals within a specific band of sustainability performance as defined by NSE Sustainability Ratings and Analytics Limited. While the source document does not provide a comparative benchmark against industry peers or prior periods, the assignment of a numeric score allows for longitudinal tracking of the company’s ESG trajectory. Investors typically use such ratings to screen for companies with robust governance frameworks and lower operational risks related to environmental or social controversies. The reliance on a SEBI-registered provider adds a layer of regulatory credibility to the score, distinguishing it from voluntary or unregulated sustainability claims.